A study of mifepristone/IFN-γ-induced apoptosis of human cholangiocarcinoma cell line FRH-0201 in vitro

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 335-342

  Sun, Qi Long ^a   Zhang, Xu Guang ^a   Xing, Quan Tai ^a   Ding, Peng ^a   Feng, Jin Bo ^a   Wu, Xiao Peng ^a   Wang, Zhan Min ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Cholangiocarcinoma; IFN ; Mifepristone; Progesterone

Indexed keywords

FAS ANTIGEN; MESSENGER RNA; MIFEPRISTONE; PROGESTERONE RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; RECOMBINANT GAMMA INTERFERON;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BAX GENE; BCL2 GENE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FAS GENE; FEASIBILITY STUDY; FLOW CYTOMETRY; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; PROTEIN EXPRESSION; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84873932814     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S36098     Document Type: Article

References (27)

1. Ahrendt SA, Nakeeb A, Pitt HA. Cholangiocarcinoma. Clin Liver Dis. 2001;5:191-218.
2. Vickers SM, Jhala NC, Ahn E Y, McDonald JM, Pan G, Bland KI. Tamoxifen(TMX/Fas) induced growth inhibition of human cholangiocarcinoma by gamma interteron. Ann Surg. 2002;235:872-878.
3. Menias CO, Surabhi VR, Prasad SR, Wang HL, Narra VR, Chintapalli KN. Mimics of cholangiocarcinoma: spectrum of disease. Radiographics. 2008;28:1115-1129.
4. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogen. 2006;25:3848-3856.
5. Yang L, Cao Z, Yan H, Wood WC. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumour cells: implication for cancer specific therapy. Cancer Res. 2003;63:6815-6824.
6. Chen Y, Xu J, Jhala N, et al. Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3′-diindolylmethane through inhibition of AKT signaling and flice-like inhibitory protein. Am J Pathol. 2006;169: 1833-1842.
7. Parrault D, Eisenhauer E, Pritchard K, et al. Phase II study of mifepristone in patients with untreated metastatic breast carcinoma: a national cancer institute of Canada clinical trials group study. J Clin Oncol. 1996;14:2709-2712.
8. Schneider CC, Gibb RK, Taylor DD, Wan T, Gerçel-Taylor C. Inhibition of endometrial cancer cell lines by mifepristone (RU840). J Soc Gynecol Investig. 1998;5:334-338.
9. Rocereto TF, Saul HM, Aikins JA Jr, Paulson J. Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol. 2000;77:429-432.
10. Kamradt MC, Mohideen N, Vaughan AT. RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells. Gynecol Oncol. 2000;77:177-182.
11. Li DQ, Wang ZB, Bai J, et al. Effects of mifepristone on proliferation of human gastric adenocarcinoma cell line SGC-7901 in vitro. World J Gastroenterol. 2004;10:2628-2631.
12. Yang LJ, Cao XT, Yu LZ. Bcl-2, bax and their roles in tumor apoptosis. Chin J Cancer Biother. 2003;10:232-234.
13. Fan ZJ, Wu Y, Wang ZJ. Expression of estrogen receptor and progesterone receptor in hilar cholangiocarcinoma and their clinical significances. Zhonghua Yi Xue Za Zhi. 2005;85:2651-2653. Chinese.
14. Chen Y, Xu J, Jhala N, et al. Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3′-Diindolylmethane through inhibition of AKT signaling and Flick-like inhibitory protein. Am J Pathol. 2006;169: 1833-1842.
15. Fiorentino M, D'Errico A, Altimari A, Barozzi C, Grigioni WF. High levels of BCL-2 messenger RNA detected by in situ hybridization in human heptatocellular and cholangiocellular carcinoma. Diagn Mol Pathol. 1999;8:189-194.
16. Nicholson DW, Thornberry NA. Apoptosis: life and death decisions. Science. 2003;299:214-215.
17. Matsumoto H, Wada T, Fukunaga K, Yoshihiro S, Matsuyama H, Naito K. Bax to Bcl-2 ratio and ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn J Clin Oncol. 2004;34:124-130.
18. Xiao G, Fang H, Xing C, Xu W. Structure, function and inhibition of Bcl-2 family proteins: a new target for anti-tumor agents. Mini Rev Med Chem. 2009;9:1596-1604.
19. Li Q, Li JJ, Zhao XB, Ji M. Study of effect of mifepristone on apoptosis of human ovarian cancer cell line 3AO. Zhonghua Fu Chan Ke Za Zhi. 2003;38:625-628. Chinese.
20. Ito Y, Takeda T, Sasaki Y, et al. Expression in cholangiocellular carcinoma is inversely correlated with biologically aggressive phenotypes. Oncolog y. 2000;59:63-67.
21. Zhang FS, Ma KS, He Z P, Dong JH. Spontaneous apoptosis and bcl-2/ bax expressions in cholangiocarcinoma and their significance. Di 3 Jun Yi Da Xue Xue Bao. 2002;24:96-99.
22. Yin P, Lin Z, Cheng YH, et al. Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells. J Clin Endocrinol Metab. 2007;92: 4459-4466.
23. Kandouz M, Siromachkova M, Jacob D, Chretien Marquet B, Therwath A, Gompel A. Antagonism between estradiol and progestin on Bcl-2 expression in breast cancer cells. Int J Cancer. 1996;68: 120-125.
24. Liu J, Matsuo H, Laoag-Fernandez JB, Xu Q, Maruo T. The effects of progesterone on apoptosis in the human trophoblast-derived HTR-8/ SV neo cells. Mol Hum Reprod. 2007;13:869-874.
25. Shimonishi T, Isse K, Shibata F, et al. Up-regulation of Fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma refect evasion from immune surveillance. Hepatology. 2000;32:761-769.
26. Liu Z, Sun QH, Yang Y, Liu JM, Peng J P. Effect of IFN gamma on caspase-3, Bcl-2 and Bax expression, and apoptosis in rabbit placenta. Cytokine. 2003;24:201-209.
27. Strand S, Galle PR. Immune evasion by tumours: involvement of the CD95 (Apo-1/Fas) system and its clinical implications. Mol Med Today. 1998;4:63-68.